Teva Pharmaceutical Industries (NYSE:TEVA)

SupremeCourt

Teva’s Latest Victory in Effort to Protect Key Patents

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent that would protect ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Compugen, Juniper Networks, Suncor, Yingli and More

Stocks have bounced after a week of selling off, with Crimea easing and with short covering. Investors still remain wary -- they want upside, but want to avoid losses in the ...
Read Full Story »
Pills

Why Teva May Be Back From the Dead

Two analyst upgrades on Friday, a new CEO and a 33% increase in its stock price since November may be confirmation that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is finally ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Alcoa, NetApp, Plug Power, Teva and More

Stocks have started pulling back, and investors want two things: upside in the market after the dust settles and not to get caught in stocks that will suffer handily if ...
Read Full Story »
investing

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

As the bull market enters its sixth year, the S&P 500 continues to set new highs and intermediate-term measures of market strength have turned positive since February. The old Wall ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Nokia, Safeway, Sirius XM, Skull Candy, Teva, and More

Stocks are hitting new highs almost daily, but investors are still leery and many worry about buying the top or getting caught by the next major market correction. 24/7 Wall ...
Read Full Story »
investing

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Most Wall Street firms run model portfolios for their institutional and retail clients. Like all portfolios, they make weighting changes based on a variety of specifics that can include everything ...
Read Full Story »
Pills

Teva Delivers on Earnings in Turnaround

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is out with its fourth-quarter earnings report, and it looks as though the bad trends may be more and more in the past. Fourth-quarter ...
Read Full Story »
DNA

Analyst Team Sees Strong Biotech Buyout Market in 2014

Mergers and acquisitions hit a very rapid pace in 2013, valued at close to $34 billion. The team at Bank of America Merrill Lynch sees 2014 being a promising year ...
Read Full Story »
Pills

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares recently hit a 52-week high after the chief financial officer of the maker of generic medicines said at a conference the company intends ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Capital One, Chesapeake, LinkedIn, Lululemon, Netflix and More

It is the first full trading week of 2014, and analysts are out with many ratings changes this Tuesday. Stocks have slid marginally since the end of 2013 after a ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

Stocks have been hitting ever higher highs going into year-end. Now investors have to be wondering how to position their portfolios for 2014 and beyond. 24/7 Wall St. reviews many ...
Read Full Story »
ten bucks

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

With less than a week left in what has been the best year for the S&P 500 since 1997, we have reviewed our top Wall Street firms for their stocks ...
Read Full Story »
gavel

Teva Secures Rights to Launch Generic Viagra

Pfizer Inc.'s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020, but Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has acquired rights to ...
Read Full Story »
Pills

Teva Prospects Keep Dimming, Even If 2014 Sales Drop-Off Limited

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has moved from a great growth story to one of promise, to one of habitual disappointment. The company's 2014 guidance is soft yet again. ...
Read Full Story »